AFIB — Acutus Medical Share Price
Last Trade - 00:00- $416.47m
- $365.89m
- $10.47m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 2.17 | 2.84 | 8.46 | 24.14 | 63.76 | 97.68% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Acutus Medical, Inc. is an arrhythmia management company. The Company designs, manufactures and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias. The Company’s product portfolio includes access sheaths, transseptal crossing tools, diagnostic and mapping catheters, ablation catheters, mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Its AcQMap System consists of the single-use AcQMap catheter as well as its console, workstation and software algorithms. With 48 ultrasound transducers interspersed between 48 biopotential electrodes, its mapping catheter collects the data required to create a map of the cardiac anatomy and electrical propagation pathways and patterns. The Company’s software algorithms analyze the biopotential data and maps any type of arrhythmia, including atrial fibrillation, as well as all supraventricular tachycardias and ventricular arrhythmias.
Directors
- R. Scott Huennekens (56)
- Vince Burgess PRE (56)
- David Roman (39)
- Steven McQuillan (58)
- Tim Corvi (52)
- David Bonita (45)
- Daniella Cramp (47)
- Andrew ElBardissi (39)
- Jim Hinrichs (53)
- Shahzad Malik (53)
- Shaden Marzouk (49)
- John Sheridan (65)
- Last Annual
- December 31st, 2020
- Last Interim
- March 31st, 2021
- Incorporated
- March 25th, 2011
- Public Since
- January 1st, 1970
- No. of Employees
- 291
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 33,613,165
- Address
- 2210 Faraday Ave Ste 100, CARLSBAD, 92008-7225
- Web
- http://www.acutusmedical.com/
- Phone
- +1 4422326144
- Auditors
- KPMG LLP
Latest News for AFIB
Upcoming events for AFIB
Q2 2021 Acutus Medical Inc Earnings Release
Q3 2021 Acutus Medical Inc Earnings Release
Similar to AFIB
ABIOMED ORD
NASDAQ Global Select Market
ACCURAY ORD
NASDAQ Global Select Market
AKOYA BIOSCIENCES ORD
NASDAQ Global Select Market
BRUKER ORD
NASDAQ Global Select Market
CERNER ORD
NASDAQ Global Select Market
FAQ
As of Today at 19:55 UTC, shares in Acutus Medical are trading at $12.39. This share price information is delayed by 15 minutes.
Shares in Acutus Medical last closed at $12.39 and the price had moved by -52.31% over the past 365 days. In terms of relative price strength the Acutus Medical share price has underperformed the S&P500 Index by -63.82% over the past year.
The overall consensus recommendation for Acutus Medical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Acutus Medical does not currently pay a dividend.
Acutus Medical does not currently pay a dividend.
Acutus Medical does not currently pay a dividend.
To buy shares in Acutus Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $12.39, shares in Acutus Medical had a market capitalisation of $416.47m.
Here are the trading details for Acutus Medical:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: AFIB
Based on an overall assessment of its quality, value and momentum Acutus Medical is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Acutus Medical is $20.67. That is 66.83% above the last closing price of $12.39.
Analysts covering Acutus Medical currently have a consensus Earnings Per Share (EPS) forecast of -$3.25 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Acutus Medical. Over the past six months, its share price has underperformed the S&P500 Index by -53.84%.
As of the last closing price of $12.39, shares in Acutus Medical were trading -37.36% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Acutus Medical.
Acutus Medical's management team is headed by:
- R. Scott Huennekens -
- Vince Burgess - PRE
- David Roman -
- Steven McQuillan -
- Tim Corvi -
- David Bonita -
- Daniella Cramp -
- Andrew ElBardissi -
- Jim Hinrichs -
- Shahzad Malik -
- Shaden Marzouk -
- John Sheridan -
We do not have data on Acutus Medical's shareholders